Imunon, Inc.
10-K
March 31, 2026
Key Highlights
- Lead drug candidate IMNN-001 showed significant survival benefits in Phase 2 ova...
- FDA has granted 'Fast Track' status to IMNN-001, accelerating the path to Phase ...
- Proprietary TheraPlas and PlaCCine platforms offer innovative DNA-based approach...
Read Analysis
π€ AI Generated